Insys Therapeutics, Inc.
DelistedCIK 1516479fmd_0BE3JKW6G270VBM3EDGHFR8R7FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Mar 31, 2019, 29 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 99 | 219 | 330 | 242 | 141 | 82 |
| Cost of revenue | 8 | 13 | 23 | 29 | 25 | 21 | 11 |
| Gross profit | 8 | 87 | 197 | 301 | 217 | 120 | 71 |
| Realized investment gains (losses) | – | – | – | 0 | – | – | – |
| Research and development | 6 | 8 | 33 | 57 | 74 | 63 | 58 |
| Selling, general and administrative | 20 | 46 | 102 | 144 | 112 | 95 | 71 |
| Total operating expenses | 31 | 54 | 136 | 211 | 210 | 339 | 199 |
| Operating income | (23) | 33 | 61 | 90 | 7 | (219) | (128) |
| Interest expense | 3 | 1 | – | – | – | – | – |
| Interest and investment income | – | 0 | 0 | 1 | 1 | 2 | 2 |
| Other non-operating income (expense) | (1) | (1) | 0 | 1 | 1 | 2 | 1 |
| Income before taxes | (24) | 32 | 61 | 91 | 8 | (217) | (126) |
| Income tax expense | 0 | (9) | 25 | 33 | 1 | 10 | (2) |
| Net income from continuing operations | (24) | 40 | 36 | 58 | 8 | (227) | (125) |
| Net income | (24) | 40 | 36 | 58 | 8 | (227) | (125) |